Enanta Pharma (NASDAQ: ENTA) reported Q4 EPS of $1.30, $0.11 better than the analyst estimate of $1.19. Revenue for the quarter came in at $67.2 million versus the consensus estimate of $68.52 million.

“Enanta has never been in a stronger position from both a financial and clinical development perspective,” said Jay R. Luly, Ph.D. President and CEO, Enanta Pharmaceuticals. “With the recent start of our Phase 2a study in RSV, we now have three Phase 2 studies ongoing in our wholly-owned development programs. Our momentum will continue into 2019, when we plan to initiate clinical testing of EDP-514, our first candidate to treat hepatitis B virus, and we expect Phase 2 data readouts in our other programs, starting with NASH and RSV studies.”

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.